The largest ever study of its type is the first to definitively show an increased risk of blood cancers in relatives of patients. A team led by scientists at The Institute of Cancer Research, London, and the German Cancer Research Centre in Heidelberg have uncovered new evidence, supporting a role for inherited genetic changes influencing the […]
AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE Researchers have discovered how some of the blood cancers known as myeloproliferative neoplasms (MPNs) evade the immune system. Their findings reveal that a subset of MPNs might be susceptible to treatment with immune checkpoint inhibitors that specifically target the PD-1/PD-L1 pathway (a signaling network that normally functions as […]
This abstract is provided by Mads Emil Bjorn & Hans Carl Hasselbalch – Department of Hematology, Region Zealand, Roskilde, Denmark Abstract Introduction: The therapeutic landscape of the Philadelphia-negative myeloproliferative neoplasms (MPNs) is markedly changing consequent to the development of JAK-inhibitors and the use of ruxolitinib (RUX) in patients with myelofibrosis (MF) and patients with polycythemia […]
2023 Update – Dr. Ruben Mesa named to Lead Atrium Health Cancer Program Publisher’s Note (David Wallace) As a Charlotte native, I’m really excited to witness the tremendous growth of our world-class cancer centers along with the groundbreaking of Charlotte’s first 4-year medical school. The school is part of the Pearl CLT innovation district. The […]
Understanding Polycythemia Vera (PV), A Rare Blood Cancer Behind the Mystery, Polycythemia Vera Every year, millions of patients, families and caregivers are impacted by cancer in the United States. Some cancers are well-known, but others are quite rare. Polycythemia Vera (PV) is part of a group of rare blood cancers called Myeloproliferative Neoplasms (MPNs). PV […]
Site by: Kaleidoscopic
